KIN-Therapeutics is developing an AI-based computational platform integrating structural bioinformatics and machine learning with experimental approaches to identify small molecules targeting specific protein kinase targets and conformations. The Kinase Inhibitor (KIN) artificial intelligence (AI) is able to generate de novo kinase drugs with optimal selectivity. This technology will allow for better design and discovery of clinically relevant kinase inhibitors, which will have significant implications for cancer, Alzheimer’s disease, and even diabetes treatments. KIN focuses on a manageable and clinically-relevant chemical space and is entering into a partnership with a biotech company to design conformation specific immune-oncology inhibitors. KIN is looking for a CEO / Chair of the Board to lead the next steps for the venture.